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In recent years, the ubiquitin-editing enzyme A20 has been shown to control a large
set of molecular pathways involved in the regulation of protective as well as self-
directed immune responses. Here, we assess the current and putative roles of A20 in
inflammatory, vascular and degenerative diseases of the central nervous system and
explore future directions of research.
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General Introduction
The ubiquitin-editing enzyme A20 has now emerged as a key negative regulator of the family of
nuclear factor-κB) transcription factors, which control a broad range of cellular activities including
cell activation, development and differentiation. NF-κB transcription factors play a central role
in the regulation of protective as well as self-directed immune responses and the pathogenesis of
human diseases including neurodegenerative diseases and aging. This review focuses on the
role of A20 in cellular hemostasis and CNS diseases. NF-κB transcription factors are dimeric
proteins composed of the Rel proteins RelA, c-Rel, RelB, p100/p52 and p105/p50. They
can be activated via canonical and a non-canonical pathways. In lymphocytes, canonical
NF-κB signaling is initiated by antigen-specific B and T cell receptors, Toll-like receptors
and other pattern recognition receptors and induces rapid and transient effects such as cell
activation and cell-type specific effector functions. The hallmark of the canonical pathway
is the signal-induced proteasomal degradation of the mainly cytoplasmic NF-kB inhibitor
IκBα. In contrast, non-canonical NF-κB signaling is mediated through specific members of
the TNFR superfamily such as CD40, B cell-activating factor belonging to the TNF family
receptor (BAFFR), lymphotoxin β-receptor and receptor activator for NF-κB (RANK), which
induce NF-κB activation to regulate more persistent cellular functions such as the formation
of lymphoid organs, cell survival and cell differentiation. The non-canonical pathway is
characterized by the signal-induced processing of the p50-precursor p100, which also has
inhibitory functions. RelB-containing NF-kB dimers are tightly regulated by a distinct subset
of genes. The activation of NF-κB transcription factors is regulated to a large extent by
post-translational modifications such as phosphorylation and by poly-ubiquitination (Chau
et al., 1989; Iwai, 2014), particularly by lys63-linked polyubiquitin chains (Wertz and Dixit,
2010; Iwai, 2014). Proinflammatory signals via TLRs/IL-1R, TNFR, IL-17R, and the T-cell
receptor (TCR) lead to Lys63 polyubiquitination of several NF-κB intermediate molecules
such as TRAF-6, RIP1, NEMO/IKKγ, and MALT1 (Deng et al., 2000; Tang et al., 2003;
Wertz et al., 2004;Chen, 2005;Oeckinghaus et al., 2007),whichcollectively result inNF-κBactivation.
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A20 as a Central Negative Regulator of
NF-κB Transcription Factors
The ubiquitin editing protein A20 is encoded by the tumor
necrosis factor-α-induced gene 3 (TNFAIP3) and has been
shown to negatively regulate NF-κB signaling by multiple
mechanisms (Coornaert et al., 2009; Vereecke et al., 2009;
Shembade and Harhaj, 2010; Catrysse et al., 2014). Binding
of the inflammatory molecules TNFα, IL-1β, LPS, CD40,
and IL-17 to their respective cell surface receptors promotes
the recruitment of specific adaptor proteins. Some of these
adaptor proteins are shared by several signal transduction
pathways. The IL-17R for instance, shares many downstream
adaptors and transcription factors with the TNFα, IL-1, and
TLR pathways. The IL-17R subunits IL-17RA and IL-17RC
do not recruit TLR-associated adaptors such as MyD88,
but instead associate with the adaptor protein Act1/CIKS.
Upon recruitment, Act1 activates pro-inflammatory signaling
pathways including TRAF6/NF-κB, MAPK and CCAAT
Enhancer Binding Proteins (C/EBP; Gaffen, 2009). Each
receptor signaling complex ultimately activates the IκB kinase
(IKK) complex. IKK activation, in turn, phosphorylates IκB
proteins, which results in their proteasomal degradation, thereby
enabling the release and translocation of NFκB into the nucleus
and subsequently the activation of NF-κB target genes. A20 has
been demonstrated to interact with several molecules within
these different signaling pathways including TNF Receptor
Associated Factor (TRAF)2, TRAF6, RIP, and IKKγ (Beyaert
et al., 2000; Boone et al., 2002; Longo et al., 2003; Garg et al.,
2013).
The human TNFAIP3 gene is localized on chromosome
6 and encodes the 790 amino acid protein A20, which
is composed of an N-terminal protease domain and seven
Cys2-Cys2 zinc finger C-terminal domains (Figure 1). A20
functions as an ubiquitin-editing enzyme (Wertz et al., 2004)
and belongs to the ovarian tumor (OTU) proteases family
of deubiquitinating (DUB) enzymes. OTU DUB enzymes
are a superfamily of cysteine proteases that cleave ubiquitin
from branched or linear polyubiquitin chains (Makarova
et al., 2000; Evans et al., 2004). In addition, A20 has also
an E3 ubiquitin ligase activity that is due to its fourth
zinc finger motif in the C-terminal domain (Evans et al.,
2004).
While A20 suppressed proximal signaling intermediates of
NF-κB activation in cells stimulated with TNFα, IL-1β, LPS,
and MDP, it failed to block direct activation of the IKK
complex by the viral protein Tax, suggesting that A20 functions
upstream of the IKK complex. This hypothesis was confirmed
by the observations that A20−/− cells displayed prolonged TNF-
induced IKK activity and that these cells were unable to terminate
NF-κB transcription (Lee et al., 2000). Although A20 inhibits
the TNFR, IL-1R, and NLR pathways, it is not known whether
A20 binds directly to any of these receptors. In contrast, A20
was found to inhibit IL-17 signaling by directly binding to the
C-terminal domain of IL-17RA (Garg et al., 2013).
More detailed insights into the mechanisms that underlie
NF-κB inactivation by A20 came from the discovery of an
OTU domain at the N-terminus of A20 (Evans et al., 2004).
Since RIP, TRAF6 and NEMO have been identified as OTU
domain substrates (Boone et al., 2004; Wertz et al., 2004;
Mauro et al., 2006), and given that these signaling molecules are
polyubiquitinated upon recruitment to their respective signaling
complexes, it was proposed that A20 attenuates NFκB signaling
by deubiquitinating these critical signaling components (Boone
et al., 2004; Wertz et al., 2004). Indeed, A20 was shown to
attenuate TLR-4/LPS, TNFα, IL-1, IL-17, and NOD2 induced
NF-κB signaling by disassembling the lys63-linked polyubiquitin
chains from RIP1, RIP2, TRAF6, and NEMO (Boone et al.,
2004; Wertz et al., 2004; Hitotsumatsu et al., 2008; Garg
et al., 2013). In addition to its deubiquitinating activity, A20
displays ubiquitin ligase activity mediated by its ZF4 domain,
which is also involved in NF-κB inhibition. To this end,
A20’s E3 ubiquitin ligase activity promotes RIP1 lys48-linked
polyubiquitination, which triggers proteasomal degradation of
RIP1 and thereby inhibits TNFα-induced NF-κB activation
(Wertz et al., 2004). In addition, A20 negatively regulates
TCR-induced activation of NF-κB by deubiquitinating Malt1
(Düwel et al., 2009). The adaptor molecule MALT-1 binds
to Carma1 and Bcl10 to form the CBM complex, which
mediates canonical NF-κB activation (Ruland et al., 2003).
FIGURE 1 | Domain structure of A20. OTU ubiquitin protease domain and zinc fingers domains are depicted in blue and yellow boxes, respectively. Picture
adopted from Enesa and Evans (2014).
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In lymphocytes, ubiquitination of MALT-1 by TRAF-6 is a
prerequisite for NF-κB activation (Oeckinghaus et al., 2007).
The fact that MALT-1 ubiquitination by TRAF6 is essential
for TCR- and BCR-induced activation of NF-κB and evidence
that MALT-1 plays an important role in the pathogenesis of
several autoimmune diseases (e.g., Multiple Sclerosis; Brüstle
et al., 2012; Mc Guire et al., 2013) and lymphomas (e.g., Marginal
B zone lymphoma and ABC-DLBCL; Ngo et al., 2006; Vega
et al., 2011) suggest that MALT-1 inhibition by A20 plays
an important role in the prevention of autoimmunity and
lymphomas (Figure 2).
A20 and Apoptosis
Although A20 was initially described as an inhibitor of TNF-
induced apoptosis (Opipari et al., 1992), its anti-apoptotic
function still remains controversial. This is largely due to
the fact that the protective effect of A20 is cell type- and
stimulus-specific (Daniel et al., 2004). A20 protects against
FIGURE 2 | The pathologic role of TCR, BCR and TH17-induced
MALT-1 in demyelination and the inhibition of this signaling pathway by
A20. As depicted in Figure 2, downstream of CBM, IKK complex is activated
by MALT-1 that in turn, plays an essential role in the development of
EAE-mediated Demyelination. MALT1, in other hand, cleaves the NF-κB
inhibitory proteins A20 and CYLD as well as the NF-κB subunit RelB in antigen
receptor-stimulated T cells and during EAE, suggesting a contribution of
MALT1 proteolytic activity in T cell activation and EAE development. A20,
negatively regulates TCR and BCR signaling to NF-κB by cleaving MALT-1
ubiquitin chains and therefore contributes to balance TCR/BCR-induced
IKK/NF-KB signaling. Activated A20 might play an important role in protecting
neural cells against autoimmune mediated demyelination.
TNF cytotoxicity in several cell lines including human breast
carcinoma MCF7 cells, murine fibrosarcoma WEHI164 cells,
murine embryonic fibroblast NIH3T3 cells, mouse osteoblastic
MC3T3-E1 cells, and human umbilical vein endothelial cells,
but fails to protect HeLa cells and lung epithelial A549 cells
(Opipari et al., 1992; Jänicke et al., 1994; Jäättelä et al., 1996;
Slowik et al., 1997; Hess et al., 1998; Natoli et al., 1998; De
Valck et al., 1999). In addition, A20 protects Jurkat cells from
TNFα- but not from Fas-mediated apoptosis (He and Ting,
2002). Moreover, stimulation of B lymphocytes via CD40 induces
A20, which in turn, inhibits B cell apoptosis (Sarma et al.,
1995). In addition to TNF-induced cell death, A20 has been
shown to inhibit cell death induced by various other apoptotic
stimuli. A20 protects endothelial cells from Fas/CD95 receptor
induced apoptosis, lymphoblastic B cells from apoptosis induced
by serum depletion, macrophages from apoptosis induced by
oxidized low-density lipoprotein (Sarma et al., 1995; Daniel
et al., 2004; Li et al., 2006), H1299 epithelial cells from
apoptosis mediated by p53 overexpression (Fries et al., 1996),
and the human microvascular endothelial cell line HMEC-1
from apoptosis induced by LPS (Hu et al., 1998). Why A20
protects only selected cell lines from apoptosis remains to be
investigated.
The inhibition of TNFα-induced apoptosis by A20 correlates
with the inhibition of phospholipase A2, reduced production
of reactive oxygen species (ROS), diminished collapse of
mitochondrial membrane potential, decreased activation of
caspase-3-like proteases and inhibition of JNK (Jäättelä et al.,
1996; Wissing et al., 1998; Lademann et al., 2001; Daniel
et al., 2004; Won et al., 2010). A20 acts early in the TNFα-
induced signaling cascade by blocking both TNFα-induced
rapid activation of the c-Jun N-terminal kinase and processing
of the receptor-associated caspase-8 (Lademann et al., 2001).
Daniel et al investigated the cytoprotective function of A20
in endothelial cells and demonstrated that A20 targets the
TNFα–induced apoptotic pathway by inhibiting the proteolytic
cleavage of caspase 8 and 2 as well as caspase 3 and 6.
Their results also showed that A20 protected endothelial cells
from Fas-mediated and natural killer cell-mediated apoptosis
through inhibition of Caspase 8 activation (Daniel et al.,
2004).
The interaction betweenA20 and anti-apoptotic proteins such
as the TAX-1 binding protein 151 (TXBP151), also suggests
a possible survival mechanism. A20 associates with TXBP151
through its C-terminal zinc finger domain, which has been
shown to mediate the anti-apoptotic activity of A20 (De Valck
et al., 1999). The observation that the over-expression of
TXBP151 inhibits TNF-induced apoptosis in some cells as well
as the fact that A20 binds TXBP151 may explain at least part
of the anti-apoptotic effects of A20. This hypothesis is further
strengthened by the observation that transfection with antisense
TXBP151 cDNA partially prevents the anti-apoptotic activity of
A20 (De Valck et al., 1999).
Another possible mechanism for the anti-apoptotic effects of
A20 has been proposed byWon et al. (2010): A20 binds to ASK1,
an important MAPKK kinase in the JNK signaling cascade,
and mediates ASK1 degradation, leading to suppression of JNK
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activation and eventually inhibition of apoptosis (Won et al.,
2010). It has been well demonstrated that persistent activation
of the JNK signaling cascade contributes to TNF-induced
apoptosis. Furthermore, A20 may inhibit apoptosis through the
suppression of pro-inflammatory cytokines (Nagamachi et al.,
2014).
A20 in Aging and Senescence
Biological aging is related to the accumulation of molecular
and cellular damage and accompanying cellular stress response
mechanisms. IKK/NF-κB transcription factors are central to
these age-related stress-response mechanisms (Solt et al., 2007)
as they are activated by inflammatory stimuli, DNA damage
and oxidative stress and control anti-oxidative and inflammatory
responses, cell survival and apoptosis. Expression of NF-κB
transcription factors is strongly associated with age in both mice
and humans and genetic blockade of NF-κB in epidermal cells
of aged mice reverts their gene expression program to that of
youngmice (Adler et al., 2007). Further evidence for a role of NF-
κB transcription factors in aging and senescence stems from the
analysis of progeroid diseases. Progeroid syndromes are a group
of genetic disorders characterized by premature development
of signs and symptoms typical for normal aging. Mice and
humans with defects in certain DNA repair enzymes develop
age-related diseases at young age suggesting a role for DNA
damage in normal aging (Hasty et al., 2003). This assumption
is further supported by similar transcription profiles found in
animal models of progeroid syndromes and normally aged mice
and humans (Schumacher et al., 2008) as well as the association
of NF-κB activity with normal and premature aging (Kriete
et al., 2008; Niedernhofer and Robbins, 2008). In addition,
signaling via NF-κB transcription factors is altered in age-
related diseases including neurodegenerative diseases, diabetes
and atherosclerosis (Verma, 2004; Chami et al., 2012; Müller-
Rischart et al., 2013; Pranski et al., 2013; Woodling et al., 2014;
Zhang et al., 2014). Numerous cell types including blood cells
divide for a limited number of divisions and then enter a non-
proliferating and apoptosis resistant state, called senescence. The
NF-κB transcription factor RelA maintains cellular senescence
by facilitating DNA repair mechanisms (Wang et al., 2009)
and overexpression of the NF-κB transcription factors RelA
and c-rel results in the induction of senescence in cultured
cells (Seitz et al., 2000; Bernard et al., 2001, 2004; Wang et al.,
2009).
Since A20 is a central inhibitor of these transcription factors,
it is conceivable that A20 has a strong impact on normal and
premature aging as well as on cellular senescence. Aged mice,
for instance, display a reduced immunologic activity of alveolar
macrophages and this age-dependent macrophage dysfunction is
associated with poor NF-κB activation and elevated expression
of A20 (Hinojosa et al., 2014). In addition, mice with B
lymphocytes deficient in A20 display elevated serum levels of IL-
6, enhanced proliferation of myeloid cells and T lymphocytes and
develop autoimmune pathology (e.g., splenomegaly, plasma cell
hyperplasia and presence of class-switched autoantibodies) with
advanced age (Chu et al., 2011). The role of A20 in aging and
senescence is only beginning to be explored and warrants further
investigation.
A20 in Autophagy
The maintenance of cellular homeostasis necessitates
mechanisms to degrade and remove cellular components
that are no longer required or dysfunctional. Autophagy is the
central catabolic mechanism of the cell and involves targeting
of unwanted components to autophagosomes, specialized
intracellular compartments, which fuse with lysosomes for
further degradation. Recently, A20 has been shown to regulate
autophagy triggered by the LPS-receptor TLR4. TLR4 signaling
leads to association of the adaptor protein TRAF-6, an E3
ubiquitin ligase and scaffold protein, with Beclin 1, a key
component of a class III phosphatidylinositol 3-kinase complex
(PI3KC3). As a consequence of association with TRAF-6,
Beclin-1 is ubiquitinated (K63), facilitating the oligomerization
of Beclin 1 and the activation of PI3KC3. This triggers the
formation of autophagosomes and induces autophagy in
macrophages (Shi and Kehrl, 2010). Consequently, A20
restricts the TLR4-induced autophagy through the reduction
of lys63-linked ubiquitination of Beclin 1 (Shi and Kehrl,
2010).
A20 has also been shown to inhibit the TNFα-mediated
JNK1 activation, an important autophagy inducing pathway
(Bubici et al., 2006). Activation of the JNK1 pathway stimulates
the dissociation of the Bcl-2/Beclin 1 complex, leading to
enhanced autophagy (Wei et al., 2008). In addition, A20
down-regulates the activity of the autophagy receptor NDP52
(Inomata et al., 2012), which plays an important role in
the selective elimination of pathogenic bacteria. During the
elimination of microbes, autophagy appears to protect cells
from excess innate immune signaling that often generates a
cytotoxic level of ROS (Thurston et al., 2009; Cemma et al.,
2011).
It has also been shown that NDP52 exerts a negative
regulatory effect on TLR-induced pro-inflammatory responses
through degradation of activated TLR adaptor molecules
and of TRAF6 (Inomata et al., 2012). In this case, NDP52
mediates aggregation of the complexes MyD88–TRAF6
and TRIF–TRAF6. This process is important for selective
degradation of unnecessary signaling molecules in lysosomes
via an autophagic mechanism. The NDP52-mediated autophagy
ultimately leads to negative regulation of TLR signaling,
suggesting that in this case activated autophagy could be an
important mechanism to maintain homeostasis in the innate
immune system. However, this effect of NDP52 could be
inactivated by A20, suggesting that A20 acts as a negative
regulator of the negative regulatory effect of NDP52 (Inomata
et al., 2012).
A20 in Lymphomas
Lymphomas are the fifth most common human malignancy and
the vast majority of lymphomas originate from the B cell lineage.
Mutations in NF-κB and JAK/STAT signaling proteins cause
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defects in B cell survival and proliferation, and contribute to
lymphomagenesis (Malynn and Ma, 2009). Since these signaling
cascades contain some ubiquitin-dependent signaling molecules
(e.g., TRAF-6), it is possible that A20 may also regulate B cell
homeostasis and activation, although the majority of studies
investigating the role of A20 in immune responses have focused
on the innate immune system.
Considering the association of chronic NF-κB activation
with tumorigenesis, it is not surprising that A20 is commonly
inactivated in tumor cells. A20 inactivation up-regulates
NF-κB-induced pro-survival genes, leading to uncontrolled
proliferation of tumor cells and enhancement of their
resistance to apoptosis (Hymowitz and Wertz, 2010). However,
reintroduction of A20 into A20-deficient tumor cell lines, leads
to the induction of cellular apoptosis and the suppression
of NF-κB activity (Honma et al., 2009). It has been shown
that A20 is the most commonly affected gene in diffuse
large B cell lymphomas and lymphoplasmacytic lymphomas
(Compagno et al., 2009; Braggio et al., 2012). For instance,
A20 is cleaved and inactivated by MALT1 following TCR
stimulation. MALT1 is a functional cysteine protease that is
constitutively active in several lymphomas such as mucosa-
associated lymphoid tissue lymphoma (MALT lymphoma;
Coornaert et al., 2008). A20-deficient cells stably generated
tumors in immunodeficient mice, whereas the tumorigenicity
was effectively suppressed by re-expression of A20 (Kato
et al., 2009). Consistent with this, expression of A20 has been
shown to cause cell death in A20 deficient lymphoma cell
lines but not in A20 competent lymphomas (Schmitz et al.,
2009).
A20 can be inactivated by promoter methylation, somatic
mutations and genomic deletions in various numbers of
lymphomas such as marginal zone lymphomas, MALT
lymphoma, primary mediastinal B cell lymphomas (PMBLs)
and Hodgkin’s lymphoma (Honma et al., 2008; Compagno
et al., 2009; Kato et al., 2009; Novak et al., 2009; Chanudet et al.,
2010) and the loss of A20 protein due to bi-allelic mutations
of TNFAIP3 occurs in some Hodgkin lymphomas and primary
mediastinal lymphomas (Schmitz et al., 2009).
Recently, the role of A20 in tumor suppression was
demonstrated in the primary cutaneous T cell lymphoma
Sézary syndrome (SS; Braun et al., 2011). Mono- and biallelic
deletions of A20 were found in 46% (6/13) of SS-patients and
reconstitution of A20 in an A20 deficient SS cell line suppressed
cell proliferation (Braun et al., 2011). Collectively, these findings
demonstrate that A20 may act as a tumor suppressor in human
lymphomas.
The Role of A20 in Autoimmune Diseases
Outside the CNS
NFκB transcription factors play a key role in the regulation of
self-directed and protective immune responses and perturbation
or excessive activation of NFκB signaling is associated to a
number of autoimmune and chronic inflammatory diseases (see
the review by Sun et al., 2013). A20 is one of the most potent
inhibitors of NFκB signaling and dysfunction of A20 results in
excessive inflammation and autoimmunity. Accordingly, mice
genetically deficient in A20 develop a lethal autoimmune disease,
characterized by increased responsiveness to TNFα- and TLR-
mediated signals and spontaneous inflammation within multiple
organs including liver, kidneys, intestines, joints and bone
marrow (Lee et al., 2000; Boone et al., 2004).
In humans, single nucleotide polymorphisms (SNPs) of
the TNFAIP3 gene have been associated with a range of
autoimmune diseases including systemic lupus erythematosus
(SLE), rheumatoid arthritis (RA), inflammatory bowel disease,
psoriasis and type one diabetes (Musone et al., 2011; Ma and
Malynn, 2012). SNPs located within the coding region of genes
may either be silent or affect protein sequence, structure and
function. More often, SNPs lie within the noncoding regions
of the gene and may affect gene transcription, splicing or
RNA stability. The wide tissue distribution of A20 is likely to
account for the broad spectrum of clinical phenotypes and the
contribution of A20 expressed in individual cell types to the
development of autoimmune diseases has thus been addressed
in a range of conditionally knock out animals.
Genome wide association studies (GWAS) identified several
SNPs within the TNFAIP3 gene and the A20 interacting
protein ABIN1 (Gateva et al., 2009) in SLE (Musone et al.,
2008). Because of the broad tissue distribution of A20 and the
lethality of A20 deficient mice, a range of conditionally knockout
animals have been generated to study tissue-specific deletion
of A20. Mice lacking A20 specifically in CD11c+ dendritic
cells show phenotypical similarities to human SLE including
glomerulonephritis, presence of antibodies against dsDNA,
ribonucleoprotein and cardiolipin, thrombocytopenia and
autoimmune lymphoproliferative syndrome (ALPS) including
enhanced spontaneous lymphocyte activation, accumulation of
double negative lymphocytes and myeloproliferative syndrome
(Kool et al., 2011). These data link A20 expression in dendritic
cells to SLE and this issue will have to be further addressed.
In addition, several SNPs in the A20 genomic locus have
been associated with RA (Bowes et al., 2010; Shimane et al.,
2010), but their relevance in disease pathogenesis has not yet
been determined. Mice deficient for A20 in myeloid cells display
inflammation within the joints, cartilage destruction and anti-
collagen antibodies but no obvious inflammation at other sites
including skin, liver, intestines and pulmonary system. This
phenotype is similar to human RA (Matmati et al., 2011). A20
deficient macrophages showed an increased degradation of the
NF-κB inhibitory molecule IκBα and produced larger quantities
of TNFα in response to TLR4 activation. Myeloid cells are
the main source of TNFα and TNFα plays a crucial role in
the pathogenesis of RA as demonstrated by the effectiveness
of TNFα blocking agents. Collectively, these data indicate that
A20 in cells of the myeloid lineage may be involved in RA
pathogenesis. In line with this, synovial fibroblasts from RA
patients display prolonged inflammatory cytokine production
and reduced expression of the inhibitory protein ABIN-3 in
response to stimulation with TNFα (Lee et al., 2013).
The common human inflammatory skin disorder psoriasis
is believed to result from an imbalance of the tightly regulated
homeostasis between keratinocytes, mesenchymal cells and
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immune cells within the skin (Nestle et al., 2009). TNFαmediated
NF-κB activation plays a central role in the pathogenesis of
psoriasis (Kumari et al., 2013) as illustrated by the responsiveness
to anti-TNFα therapy (Lowes et al., 2007). SNPs in the TNFAIP3
gene, but also in other immune-regulatory genes including
HLA-C, TNIP1/ABIN-1 and IL-23A (Nair et al., 2009; Strange
et al., 2010; Johnson-Huang et al., 2012) have been associated to
psoriasis and polymorphisms in the TNFAIP3 gene correlate to
responsiveness to TNFα blockers in psoriasis patients (Tejasvi
et al., 2012). In animal models, inhibition of NF-κB activity by
deletion of IκB kinase 2 in keratinocytes induces inflammatory
skin lesions (Pasparakis et al., 2002) while ablation of A20 in skin
keratinocytes results in keratinocyte hyperproliferation but not
inflammation (Lippens et al., 2011). In contrast, genetic ablation
of ABIN-1 in CD11c+ dendritic cells increases experimental
psoriasis in mice (Callahan et al., 2013). These data suggest that
A20 or A20 interacting proteins could be impaired in dendritic
cells of psoriatic patients.
A20 in Brain Autoimmune Disease
Multiple sclerosis (MS) is the most prevalent of all autoimmune
diseases of the central nervous system (CNS) that include
neuromyelitis optica, limbic encephalitis and rasmussens
encephalitis (Waubant and Cross, 2014). MS is characterized by
infiltration of T lymphocytes, B lymphocytes and macrophages
into the CNS and immune-mediated destruction of CNS
myelin and neurons. In about 70% of patients, MS initially
follows a relapsing remitting course, which is accompanied by
spontaneous increase and decrease of inflammatory activity
within the CNS. The cause of MS and the factors that regulate
inflammatory activity are only poorly understood. Low vitamin
D serum concentrations, tobacco smoking, Epstein Barr Virus
and high sodium intake have been identified as risk factors for
MS and more than 100 gene variants have been associated with
the disease, but each showing only a weak correlation (Beecham
et al., 2013). Among these, SNPs within the TNFAIP3 gene
have been associated to MS in a meta-analysis of genome-wide
association scans that included 2624 subjects with MS and 7220
control subjects (De Jager et al., 2009).
NF-κB transcription factor expression was found to be
increased in macrophages of MS patients and down regulated
after treatment with interferon beta, a drug that suppresses
MS disease activity (Christophi et al., 2009). Consistent with
this, TLR induced cytokine production was increased in MS
patient’s macrophages (Christophi et al., 2009). These data
would fit to the hypothesis, that MS is related to diminished
function of A20 in macrophages. To date, this issue has only
been addressed in a single study that found reduced levels
of A20 mRNA in monocytes and to a lesser extent in CD4+
helper T cells in patients with MS (Navone et al., 2014).
Further research could clarify whether A20 protein is altered
in macrophages and possibly other types of antigen presenting
cells in MS patients and whether A20 expression correlates
to different stages or activity of the disease or responsiveness
to specific immunomodulatory treatment. In this context it
is important to note that TNFα directed therapies do not
ameliorate MS disease activity. While anti-TNFα therapy is
exquisitely effective in RA, psoriasis and inflammatory bowel
disease, it can worsen MS disease activity (The Lenercept
Multiple Sclerosis Study Group and The University of British
Columbia MS/MRI Analysis Group, 1999) or induce MS
in individuals treated for systemic autoimmune conditions
(Hare et al., 2014). A further clarification of the role of
A20 and A20 related molecules in these conditions could
thus provide important insights into the specific underlying
disease mechanisms and provide new concepts for individualized
therapy.
In experimental autoimmune encephalomyelitis (EAE), the
animal model of MS, NF-κB transcription factors critically
determine disease activity. Inhibition of NF-κB by blocking of
IKK protects mice from EAE (Dasgupta et al., 2004). Due to
the broad tissue distribution of NF-κB, it is obviously hard
to experimentally attribute this effect to specific cell types,
i.e., immune cells vs. CNS resident cells. Mice deficient for
p50-NF-κB display markedly reduced EAE disease severity and
reduced peripheral T cell activation and differentiation, while the
numbers of CNS infiltrating immune cells (CD3+ T cells, B220+
B lymphocytes and CD11b+ macrophages) in mice with severe
EAE is significantly increased in NF-κB1 deficient animals as
compared to wild-type littermates (Hilliard et al., 1999).
In line with this, mice deficient in the NF-κB regulator
MALT1 do not develop EAE, despite strong lymphocytic
infiltration into the CNS while adoptively transferred wild type
T helper cells efficiently induce EAE in MALT1−/− hosts.
MALT1 deficient Th17 cells show reduced expression of the
effector cytokines IL-17 and GM-CSF (Brüstle et al., 2012).
Collectively, these data point towards a role for NF-κB in
immune cells as opposed to CNS cells in the regulation of
CNS-directed immunity. In spite of these observations, NF-
κB also largely regulates activity of neurons and glia cells
during CNS inflammation. Inactivation of NF-κB specifically
in astrocytes leads to improved clinical outcome of EAE and
reduced expression of inflammatory cytokines within the CNS in
mice (Brambilla et al., 2014). In line with this, mice lacking A20
in astrocytes display increased EAE disease severity (Wang et al.,
2013) and A20 deficient astrocytes showed increased activity of
NF-κB and produced larger amounts of chemokines in response
to stimulation with the inflammatory cytokines TNFα, IL17 and
GM-CSF. These data consistently provide evidence for a role of
NF-κB in astrocytes in the regulation of CNS autoimmunity and
astrocyte-mediated neurotoxicity.
A20 and Neurodegeneration
Functional NFκB complexes are present in neurons, astrocytes,
microglia, and oligodendrocytes of the CNS (O’Mahony et al.,
2006; Camandola and Mattson, 2007; Figure 3). Interestingly,
similarly to B cells, neurons exhibit high constitutive NFκB
activity; NFκB is present in synapses, where it is readily available
to respond to synaptic stimulation. In fact, it is to date the
only transcription factor that has been shown to be activated
locally in synapses (Meffert et al., 2003; Marcora and Kennedy,
2010). NFκB is, contrary to many other synaptically relevant
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FIGURE 3 | The essential role of A20 in the regulation of NF-κB in
neurons, astrocytes and microglia. Several factors including inflammation,
brain injury and stroke and toxins can induce the production and activation of
NF-κB transcription factor in various cells of CNS. Activation of NF-κB, results
in the induction of several inflammatory mediators as well as the activation of
Ubiquitin-editing enzyme A20. A20, in turn, negatively regulates NF-κB
signaling and preserves CNS-specific homeostasis.
transcription factors, responsive to low-frequency stimulation
coupled with long-term depression (LTD) and it is further
activated in the context of long-term potentiation (LTP; Meffert
et al., 2003; Oikawa et al., 2012). Various neurotransmitters,
including glutamate, Ca2+ influx, ROS and cytokines, such
as TNF and IL-1, and β-amyloid precursor protein stimulate
receptors mediating NFκB activation in neurons (Albensi and
Mattson, 2000; Kaltschmidt et al., 2005). Consequently, an
important role for NFκB has been demonstrated in the regulation
of neurogenesis, neuritogenesis, synaptogenesis, and of learning
and memory (O’Mahony et al., 2006; Zhang and Hu, 2012;
Methot et al., 2013; Mihalas et al., 2013). In contrast, in
astrocytes or in microglia, NFκB signaling does not appear to be
constitutively active, nor is it responsive to activation by calcium,
but is instead readily induced by proinflammatory molecules,
accompanied by the production of a multitude of cytokines
and chemokines, eicosanoids and reactive nitrogen and oxygen
species by glial cells.
Not surprisingly, NFκB has been implicated in the
pathogenesis of Parkinson’s disease (PD), Huntingdon’s disease
(HD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis
(ALS), MS and stroke (Kaltschmidt et al., 1999; Dasgupta et al.,
2004; van Loo et al., 2006; Ghosh et al., 2007; Sarnico et al.,
2009; Marcora and Kennedy, 2010; Baiguera et al., 2012; Hsiao
et al., 2013). Much of the role of NF-κB in neurodegenerative
diseases stems from its part as a regulator of inflammatory
actions either in immune cells or in macroglia. Nonetheless,
the role of NF-κB in the regulation of synaptic efficacy should
not be ignored either, when considering the ultimate etiology
of neurodegenerative diseases (Dasgupta et al., 2004; Ghosh
et al., 2007; Marcora and Kennedy, 2010). Dissociated cultures of
hippocampal neurons from mice exhibiting delayed synthesis of
IκBα are hyperexcitable, whereas persistent IκB kinase complex
(IKK)/NF-κB signaling in forebrain neurons does not induce
overall neuroinflammation, but elicits a selective inflammatory
response in the dentate gyrus of the hippocampus, accompanied
by decreased neuronal survival and apoptosis, independent of
neurodegeneration (Maqbool et al., 2013). In line with this,
enhanced IKK-NFκB signaling upon inflammation in HD
astrocytes plays a detrimental role in neuronal survival in the
Htt mouse model and in HD patients (Hsiao et al., 2013). On
the other hand, inhibition of IKK complex in microglia and
astrocytes within the substantia nigra pars compacta, but not
in neurons, where NF-κB activity is also upregulated, improves
motor functions in the MPTP mouse model of PD (Ghosh
et al., 2007). Furthermore, reduced nuclear localization of the
Rel-A (p65) subunit of the NFκB dimer confers protection
in the study mentioned above, while a deficiency in the c-Rel
subunit of NFκB renders mice to develop parkinsonism with
aging, characterized by microglia, but not astrocyte, activation
(Baiguera et al., 2012). Finally, in the middle cerebral artery
occlusion (MCAO) model of stroke the outcome of the insult has
been shown to depend on the NFκB dimer subunit composition
in the affected tissue: c-Rel is in general anti-apoptotic and
target genes of c-Rel include several antioxidant and anti-
apoptotic genes, whereas RelA-containing NF-kB dimers
facilitate apoptosis (Sarnico et al., 2009). Taken together, it
appears that the majority of the detrimental NFκB activation
in CNS disorders takes place in micro- and macroglia cells,
not in neurons. Moreover, some of the discrepancies in the
literature concerning the role of NFκB in neurodegenerative
diseases may result from the formation of NFκB dimers
of different subunit composition in each particular model
system applied, followed by activation of a characteristic set of
target genes. Notably, the NFκB target genes activated during
basal synaptic transmission in neurons have not yet been
identified.
How the activity of the NFκB dimer is regulated in the
CNS remains poorly understood. Different cell types within
the CNS may putatively utilize cell type and cell sub-type
specific regulators reflecting the unique functions of NFκB in
glial cells as compared to neurons. Recent reports provide
evidence that A20 is crucial for NF-κB pathway regulation
in CNS disorders. Astrocyte restricted deletion of A20, but
not a similar deletion in neurons, aggravated the outcome
of EAE leading to chemokine overproduction, increased
numbers of encephalitogenic CD4+ T lymphocytes and cytokine
production, enhanced recruitment of inflammatory leukocytes
and demyelination in the spinal cord (Wang et al., 2013).
Additionally, SNP of A20 have been linked to susceptibility to
MS (De Jager et al., 2009). In clinical studies decreased A20
mRNA expression was detected in MS patients compared to
control individuals. Low A20 amounts are indicative for a more
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severe course of the disease (Gilli et al., 2011). Furthermore,
increased cerebrospinal fluid (CSF) levels of the chemokine
CXCL13, a prognostic MS marker, have been reported for
MS patients with A20 SNPs (Lindén et al., 2013). A20 has
also been implicated in the regulation of NF-κB activation
in a microglia cell line, though in vivo evidence for the
role of A20 in the regulation of microglia NF-κB activity
is still missing (Dalal et al., 2012). Finally, studies exploring
the function of A20 in NF-κB regulation upon MCAO have
different conclusions, one stating reduced infarct volume and
improvement of neurological deficits in A20 gene deficient
rats, though whether these effects were due to reduced NF-κB
activity was not examined (Yu et al., 2006). However, another
work employing knockout mice for A20, either in the CNS
or specifically in neurons, did not detect differences in infarct
volume when assessed 24 h after MCAO, although MCAO
upregulated A20 expression in wild type mice (Mc Guire et al.,
2013).
Consequently, some initial evidence exists to support the
proposal that A20 would regulate NF-κB activation in the
CNS. To investigate this, Pranski and colleagues examined
the expression of ‘‘NF-κB editing complex’’ components, A20,
RING finger protein 11 (RNF11), Itch (an E3 ligase) and Tax
binding protein (TAX1BP1), in the normal human brain by
quantitative PCR (RT-PCR) and immunohistochemistry (IHC;
Pranski et al., 2013). Both A20 and RNF11 were detected by RT-
PCR in the samples of the frontal cortex, striatum, hippocampus,
pons and medulla. By IHC predominantly neuronal but also
glial expression was reported for RNF11, Itch and TAX1BP1
in the brain structures mentioned above. Unfortunately, A20
protein itself was not detectable with the antibodies used
and the putative cell type specific expression of A20 in the
healthy CNS remains an unresolved issue. Previously, RNF11
has been demonstrated to localize to Lewy bodies in Parkinson
disease brain (Anderson et al., 2007). Using murine primary
neurons depleted for RNF11, the same lab also showed that
RNF11 depletion leads to nuclear localization of RelA (p65)
(Pranski et al., 2013). Nonetheless, RNF11-mediated inhibition
of NF-κB was found to exacerbate 6-OHDA toxicity, a PD
disease model, in in vivo and in vitro experiments, whereas
reduced expression of RNF11 and consequently increased NF-
κB activation protected against neurodegeneration (Pranski et al.,
2013).
Taken together, A20 is emerging as an important regulator
of NF-κB activation in astrocytes and possibly in neurons
upon insult. Whether it may contribute to the regulation of
constitutive NF-κB activity in neurons or in neurodegenerative
processes is currently an open question. Both in microglia
and in astrocytes, NF-κB activation is usually transient,
whereas neurons exhibit sustained NF-κB activity. Persistent
activation is usually associated with inflammation. This may
be reflected in the manner NF-κB activity is regulated in
neurons vs. glial cells and in the molecules involved. Two
other A20 related deubiquitinating cysteine proteases Cezanne
1 (Cellular zinc finger anti- NF-κB Otud7b/Ovarian tumor
domain) and Cezanne 2 (Otud7a) were identified on the
basis of their overall sequence similarity to A20 and due to
their potential to regulate NF-κB signaling and were hence
termed to belong to ‘‘A20 family of proteins’’ (Evans et al.,
2001; Enesa et al., 2008). The molecules share the N-terminal
OTU domain that mediates deubiquitination and regulation
of NF-κB signaling. Cezanne also bares a single conserved
zinc finger motif that is similar to the A20 zinc finger motifs
conferring E3 ubiquitin ligase activity to A20 (Evans et al., 2001;
Ma and Malynn, 2012). Expression of all Cezanne molecules,
like that of A20, is induced by NF-κB creating thereby a
negative feedback loop for NF-κB signaling (Luong et al.,
2013).
Yet, although A20 and Cezanne possess overlapping
structural and biochemical properties, they exert unique
functions by targeting distinct forms of poly-ubiquitin (Bremm
et al., 2010). This, together with the fact that their cell and
tissue specific expression profiles differ, imply that A20 and
Cezanne molecules might have to some extent overlapping,
yet simultaneously unique functions as regulators of NF-κB
signaling. Cezanne 1 is ubiquitously expressed in various cell
types and tissues, though the brain seems to exhibit the highest
Cezanne 1 mRNA levels (Hu et al., 2013; Luong et al., 2013).
Cezanne 2 expression is instead restricted to the central nervous
system (CNS), where it is particularly abundant in the cerebral
cortex and in the cerebellum (Hu et al., 2013). On the other hand,
A20 is specific to immune cells, yet inducible in pathological
conditions in various other cell types including macroglia (Wang
et al., 2013).
Using Cezanne 1 knockout mice, a recent study revealed
Cezanne 1 as a specific regulator of non-canonical NF-κB
signaling (Hu et al., 2013). Cezanne 1 deficiency in mice
does not result in a significant effect on canonical NF-κB
activation, but causes hyper-activation of the non-canonical
NF-κB pathway. It was also noted that Cezanne 1 does not
affect the basal activation of non-canonical NF-κB signaling, but
controls only signal-induced NF-κB activity. These observations
are of interest as A20 is specific for the canonical NF-κB
pathway and no other negative regulator of the non-canonical
NF-κB signaling has been identified this far. Nonetheless,
some other works have identified Cezanne 1, whose expression
is up-regulated by hypoxia, as a negative regulator of the
canonical NF-κB signaling, among others in an ischemia-
reperfusion model (Enesa et al., 2008; Luong et al., 2013).
These initial findings, together with the fact that Cezanne 1
regulates nuclear localization of DJ-1/Parkin 7, mutated forms of
which are associated with the early-onset form of PD (McNally
et al., 2011; Saito et al., 2014), may suggest potential roles
for Cezanne proteins in the regulation of NF-κB activity in
inflammatory responses to ischemia, and in neurodegenerative
diseases.
The Role of A20 in Brain Tumors
Evidence from animal models and human studies support the
concept that chronic inflammation promotes sustained NF-κB
activation, which in turn facilitates tumorigenesis in a large
variety of tissues (Conti et al., 2005; Mattson and Meffert, 2006).
The role of A20 in the development of tumors of the CNS
is less clear and controversial. A20 was found to be largely
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overexpressed in human glioblastoma stem cells (GSCs) and
glioma tissue samples (Guo et al., 2009; Hjelmeland et al.,
2010) and siRNA-mediated downregulation of A20 in U87
glioblastoma cells as well as in a mouse Xenograft tumor model
led to significantly reduced tumor growth and tumor size (Guo
et al., 2009). In line with this, inhibition of A20 expression in
glioma stem cells decreased their growth and their tumorigenic
potential (Hjelmeland et al., 2010). In addition, down-regulation
of A20 has been correlated to the development of multiple drug
resistance (MDR) in glioblastoma cells (Bredel et al., 2006) MDR
was proposed to be mediated by a RIP-dependent signaling
cascade that leads to NF-κB-induced resistance formation and
glioblastoma cell survival. In contrast to these results, expression
of A20 was negatively correlated to clinical outcome in a cohort
of glioblastoma patients (Bredel et al., 2006).
A possible mechanism for A20’s tumor enhancing function
in glioblastoma and GSCs might be the A20-induced apoptotic
resistance. Since A20 is a potent anti-apoptotic molecule, it
sustains the resistance of gliomas to apoptosis and promotes their
proliferation. In glioma cells, A20 displays strong anti-apoptotic
activity, even though it inhibits the anti-apoptotic activity of
NF-κB (Guo et al., 2009). Taken together, A20 contributes to
cell survival in glioma cells and may be an attractive target for
glioma therapy. Its function may well vary in different tumors of
different cellular origin.
A20 in Cerebral Ischemia and Post-Ischemic
Apoptosis
Brain infarction is accompanied by ischemic tissue damage
as well as infiltration of inflammatory cells and immune-
mediated neuronal damage (Iadecola and Alexander, 2001). The
central role of NF-κB in ischemic tissue damage and associated
inflammatory mechanisms is well established and indicates a
potential role for A20 in the control of ischemia-induced brain
damage. Although A20 is up-regulated in the brain of mice after
permanent MCAO, deletion of A20 in either neurons or CNS
cells does not alter ischemia-induced tissue damage (Mc Guire
et al., 2013). However, over-expression of A20 in primary rat
hippocampal neurons and SH-SY5Y cells has been shown to
result in the reduction of infarct volume and improvement of
neurological deficits following experimentally induced cerebral
ischemia (Yu et al., 2006). Furthermore, inhibition of TNFα-
induced apoptosis in primary rat hippocampal neurons has
also been demonstrated, suggesting a possible neuroprotective
function of A20 in ischemic damage.
Final Conclusion
A20 has been firmly established as a central negative regulator
of NF-κB transcription factors but its impact on cellular and
organismic functions is only beginning to be assessed. A20
inhibits apoptosis in several cell types, enhances cell survival and
has implications for cellular senescence and aging. It appears to
act as a tumor suppressor in lymphomas and deletion of A20
within the immune system results in enhanced inflammation and
spontaneous autoimmunity. Impaired A20 function in antigen
presenting cells has been associated with human autoimmune
diseases including psoriasis, RA and MS, but the underlying
cellular and molecular mechanisms remain to be addressed.
Within the CNS, A20 and the A20 related deubiquitinating
proteases Cezanne 1 and Cezanne 2 probably have partially
overlapping functions in the regulation of NF-κB in astrocytes
and possibly in neurons. Initial results suggest yet to be
determined roles of A20 and Cezanne 1 in cerebral ischemia,
CNS inflammation and neurodegenerative diseases. The role of
A20 in CNS autoimmune disease is largely unknown. However,
indirect evidence indicates that A20 function may be impaired
in macrophages in MS, which is in line with the observation,
that NF-κB in astrocytes and microglia is particularly responsive
to inflammatory stimuli. NF-κB has been implicated in the
pathogenesis of a variety of neurodegenerative diseases and A20,
a key regulator of NF-kB activity, as well as additional A20-
related proteases are likely to be involved in Alzheimer’s disease,
Parkinson’s disease and stroke.
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